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Abstract
Insulin resistance, reduced b-cell mass, and hyperglucagonemia are consistent features in type 2 diabetes mellitus (T2DM).
We used pancreas and islets from humans with T2DM to examine the regulation of insulin signaling and cell-cycle control of
islet cells. We observed reduced b-cell mass and increased a-cell mass in the Type 2 diabetic pancreas. Confocal microscopy,
real-time PCR and western blotting analyses revealed increased expression of PCNA and down-regulation of p27-Kip1 and
altered expression of insulin receptors, insulin receptor substrate-2 and phosphorylated BAD. To investigate the
mechanisms underlying these findings, we examined a mouse model of insulin resistance in b-cells – which also exhibits
reduced b-cell mass, the b-cell-specific insulin receptor knockout (bIRKO). Freshly isolated islets and b-cell lines derived from
bIRKO mice exhibited poor cell-cycle progression, nuclear restriction of FoxO1 and reduced expression of cell-cycle proteins
favoring growth arrest. Re-expression of insulin receptors in bIRKO b-cells reversed the defects and promoted cell cycle
progression and proliferation implying a role for insulin-signaling in b-cell growth. These data provide evidence that human
b- and a-cells can enter the cell-cycle, but proliferation of b-cells in T2DM fails due to G1-to-S phase arrest secondary to
defective insulin signaling. Activation of insulin signaling, FoxO1 and proteins in b-cell-cycle progression are attractive
therapeutic targets to enhance b-cell regeneration in the treatment of T2DM.
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Introduction
Type 2 diabetes mellitus results from a combination of insulin
resistance, defects in insulin secretion and hyperglucagonemia. It
has been recognized for several decades that overt type 2 diabetes
is delayed for a considerable period by the ability of pancreatic
islets to compensate for the ambient insulin resistance, glucose
toxicity and amyloid deposition [1,2,3,4,5,6,7,8,9,10]. However,
the pathways that underlie these failed compensatory mechanisms
in humans are not fully defined. Longitudinal studies in rodent
models of diabetes clearly indicate that islets can compensate for
the insulin resistance by replication and neogenesis [11,12,13]. An
increase in b-cell volume in insulin-resistant obese non-diabetic
humans suggests that an islet compensation likely occurs in
humans as an initial adaptive response to insulin resistance, to
delay the onset of hyperglycemia in type 2 diabetes [14,15].
However, examination of dynamic changes in b-cell mass in
humans is limited by the techniques available to gain experimental
access to islets in vivo. Thus, most studies to date have focused on
studying post-mortem pancreas sections [12,14,15,16,17] and in
some cases using islets isolated from patients with type 2 diabetes
[18,19,20,21].
b-cell mass is regulated by a balance between generation of new
b-cells (by replication and neogenesis) and b-cell death (apoptosis)
[21,22,23,24]. Most studies to date suggest that a decrease in b-cell
mass in established cases of human and non-human primates
affected by type 2 diabetes is due to enhanced apoptosis [6,15,16].
Interestingly, studies in rodents indicate that adult b-cell mass is
maintained by replication of existing b-cells involving cyclin D1
and D2 or both [22,25,26,27]. A role for b-cell replication is also
evident in the compensatory response to insulin resistance that has
been linked to the homeodomain transcription factor PDX-1 and
the forkhead transcription factor [28,29]. Other studies in rodents
and in human islet precursor cells suggest that a reversible process
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of de-differentiation and differentiation contributes to b-cell
expansion, and new b-cells may form by transdifferentiation
[30,31,32]. While studies in both rodents and humans indicate a
role for insulin signaling proteins in the modulation of islet
secretion and function, and growth factor inhibitors have been
suggested to play a role during differentiation of embryonic stem
cells, evidence for a potential link between altered growth factor
signaling and b-cell regeneration in the context of type 2 diabetes
is not fully understood [9,13,19,33,34].
In this study we have examined pancreas and islets from
patients with type 2 diabetes for evidence of b-cell replication and
sought to determine changes in expression of proteins involved in
insulin signaling and b-cell cycle control using high resolution
confocal imaging of pancreas sections and RT-PCR of islets
isolated from diabetic patients. We have focused on proteins in the
insulin/IGF-I signaling pathway and in cell cycle control since
both pathways are critical for maintenance of adult cell mass.
Furthermore, based on a mouse model showing similar defects, we
provide mechanistic evidence for a role for insulin signaling and
FoxO1 in the modulation of b-cell survival and proliferation.
Materials and Methods
Patients
The clinical characteristics and laboratory data of the group of
patients with T2DM and controls are provided in Table 1 and
Table 2. The pancreatic specimens were carefully selected in
relation to their morphological quality and all routine immuno-
histochemical staining performed using antibodies directed against
pancreatic hormones were subject to quality control using
appropriate positive and negative controls. All specimens were
fixed in buffered formalin (formaldheyde 4% and acetate buffer
0.05 M) for 24 hours and routinely embedded in paraffin. Five
micrometer thick sections were stained with hematoxylin-eosin for
morphological evaluation. Human pancreas specimens from
donors were fixed and immunostained as previously described
[8,9,35,36].
Ethical approval
All experiments in regard to use of human tissues were in
compliance with and following approval of the Institutional
Review Board of the Joslin Diabetes Center. Human pancreata
were collected from brain-dead organ donors after informed
consent was obtained in writing from family members, as
previously reported [37]. The islet isolation centers had approval
to isolate islets for scientific research if they were not considered
suitable for clinical islet transplantation, and were in accordance
with the Institutional ethical requirements. Animal experiments
were performed in compliance with the Instituional Animal Care
and Use Committee (IACUC) of the Joslin Diabetes Center,
Brandeis University and Harvard Medical School and in
compliance with the policies of the National Institutes of Health.
Immunofluorescence by confocal and light microscopy
Staining with primary antibody was followed by incubation with
FITC-, TRITC, or CY5-conjugated secondary antibodies. Islets
were imaged using a Bio-Rad MRC 1024 confocal laser scanning
microscope. To reduce the bleed through from below, confocal
images were acquired sequentially, using the LaserSharp2000
software with a low iris diameter. The florophores (FITC, TRITC
and Cy5) are all commonly used for triple immunostaining and the
bleed through for these fluorophores is negligible when sequential
Table 1. Non-diabetic multiorgan donors.
N6
AGE
(YRS)
GENDER
(M/F)
WEIGHT
(Kg)
HEIGHT
(m)
BMI
(Kg/m2) CAUSE OF DEATH
1 58 M 86 1,75 28,08 TRAUMA
2 72 F 70 1,70 24,22 CEREBRAL HEMORRHAGE
3 75 F 60 1,65 22,04 CEREBRAL HEMORRHAGE
4 67 F 65 1,65 23,88 CEREBRAL HEMORRHAGE
5 79 M 65 1,70 22,49 CEREBRAL HEMORRHAGE
6 73 M 80 1,80 24,69 CEREBRAL HEMORRHAGE
7 57 F 57 1,55 23,73 CEREBRAL HEMORRHAGE
8 63 M 55 1,65 20,20 CEREBRAL HEMORRHAGE
9 81 M 85 1,80 26,23 CEREBRAL HEMORRHAGE
10 55 M 75 1,80 23,15 CEREBRAL HEMORRHAGE
11 78 M 70 1,70 24,22 CEREBRAL HEMORRHAGE
12 82 M 70 1,70 24,22 CEREBRAL HEMORRHAGE
13 62 F 63 1,56 25,89 CEREBRAL HEMORRHAGE
14 73 M 70 1,70 24,22 CEREBRAL HEMORRHAGE
15 73 M 80 1,74 26,42 CEREBRAL HEMORRHAGE
16 69 F 65 1,55 27,06 CEREBRAL HEMORRHAGE
17 76 M 90 1,85 26,30 TRAUMA
18 68 M 85 1,8 26,23 CEREBRAL HEMORRHAGE
MEAN 70,06 12M/6F 71,72 1,70 24,63
± SEM 8,29 10,56 0,09 1,97
The details of the non-diabetic organ donors. Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0028050.t001
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scanning is employed. Identical parameters (laser power, iris
diameter and gain) were maintained to acquire images from all
sections. Background signal due to non-specific binding was
subtracted from ‘‘test’’ images. The confocal imaging techniques
employed in these studies are consistent with previously published
methods [8]. Immunofluorescence studies reported in figure 1c–i
were performed on seven different control and T2D subjects and
similar results were obtained. Islet numbers were evaluated by
counting 10 fields at 406magnification.
Quantification of endocrine cells in healthy subjects and
T2D patients
Analysis was performed on seven healthy controls and seven
T2D subjects, and a total of 100 controls and 100 T2D islets were
analysed. Two sections for each pancreas were triple stained with
glucagon, insulin and somatostatin followed by incubation with
FITC-, TRITC- and CY5-conjugated secondary antibodies.
Fourteen to 16 islets per subject were randomly selected and
imaged with a confocal microscope and the number of insulin-,
glucagon- or somatostatin-positive cells per islet was manually
counted in blind by two independent observers. Islets with less
then 30 endocrine cells were not included in this analysis. The
number of PCNA-positive cells was manually counted blind by
two independent observers. Data are expressed as a percentage of
total insulin-, glucagon- or somatostatin-positive cells per islet.
Immunohistochemistry for Ki67
To evaluate Ki67 protein expression, immunohistochemical
staining using the ABC peroxidase technique was performed on
formalin fixed and paraffin embedded tissues [36]. Briefly, three
micrometer thick sections were mounted on poly-L-lysine coated
slides, de-paraffinized and hydrated through graded alcohol to
water. Endogenous peroxidase activity was inhibited by dipping
sections in 3% hydrogen peroxide for 10 minutes at room
temperature. After heat antigen retrieval in a microwave oven,
primary Ki67 antibody (monoclonal, clone MIB1 at 1:100, Dako,
Copenhagen) incubation was performed at 4uC for 18–20 hours
and was followed by the avidin-biotin complex (ABC) procedure.
Sections were then immersed in 0.03% 3,39 diaminobenzidine
tetrahydrochloride and counterstained with Harris’ hematoxylin.
RT-PCR
Isolated islets were purified from five type 2 diabetic subjects and
seven normoglycemic controls using the modified Ricordi method
as described in Gunton et al. Semi-quantitative-PCR of insulin
receptor isoforms was performed as described previously [19].
Western blotting of islets from patients with T2DM
Insulin receptor (IR), insulin receptor substrate-1 (IRS1), insulin
receptor substrate 2 (IRS2) and phosphatidylinositol 3-kinase p110
alpha (PI3K) expression was determined by immunoblotting as
reported previously [38]. Aliquots of islet cell lysates obtained from
400 hand-picked islets and containing 250 mg protein, were
immunoprecipitated by incubation with antibodies against total
(anti-IR antibody, provided by G. Sesti; anti-IRS1 antibody, Santa
Cruz Biotechnologies, CA, USA; sc-17200; anti-IRS2 antibody,
Millipore, Massachusetts, USA; 06-506; and anti-PI3K, Santa
Cruz Biotechnologies, CA, USA; sc-7174) and activated (anti IRS-
1/2, Tyr 612, Santa Cruz Biotechnologies, CA, USA; sc-17195)
proteins. After immunoprecipitation, bound antibodies were
detected using procedures performed according to the manufac-
turer’s instructions (ECL, Amersham Biosciences, Buckingham-
shire, UK). Bands of interest were quantified by a densitometer
(GS 690 BioRad, Laboratories CA, USA) using a MultiAnalyst/
PC-PC Software for Bio-Rad’s Image Analysis Systems, Version
1.02 (BioRad Laboratories CA, USA).
Animals, cell lines and DNA content analyses
b-cell specific insulin receptor knockout (bIRKO) mice and
control mice (mice expressing Cre recombinase on the rat insulin
Table 2. Type 2 diabetic multiorgan donors.
N6
AGE
(YRS)
GENDER
(M/F)
WEIGHT
(Kg)
HEIGHT
(m)
BMI
(Kg/m2) CAUSE OF DEATH
KNOWN
DURATION
OF DIABETES ANTIDIABETIC THERAPY
1 54 M 90 1,80 27,8 CEREBRAL HEMORRHAGE N.A. SULPHONYLUREA + METFORMIN
2 49 M 110 1,82 33,2 CEREBRAL HEMORRHAGE N.A. DIET
3 74 M 99 1,95 26,0 CEREBRAL HEMORRHAGE 8 METFORMIN
4 70 F 70 1,65 25,7 CEREBRAL HEMORRHAGE 5 SULPHONYLUREA + METFORMIN
5 66 M 75 1,80 23,1 CEREBRAL HEMORRHAGE 7 SULPHONYLUREA + METFORMIN
6 56 M 100 1,80 30,9 CEREBRAL HEMORRHAGE 3 DIET
7 70 M 90 1,79 28,1 CEREBRAL HEMORRHAGE N.A. SULPHONYLUREA
8 62 M 85 1,80 26,2 CEREBRAL HEMORRHAGE N.A. SULPHONYLUREA
9 67 F 70 1,75 22,9 CEREBRAL HEMORRHAGE 15 INSULIN
10 66 F 85 1,80 26,2 CEREBRAL HEMORRHAGE 20 INSULIN
11 75 F 80 1,65 29,4 TRAUMA 6 SULPHONYLUREA
12 75 F 75 1,65 27,5 ICTUS 11 SULPHONYLUREA + METFORMIN
13 63 M 90 1,75 29,4 CEREBRAL HEMORRHAGE 6 SULPHONYLUREA+METFORMIN+INSULIN
14 68 F 80 1,65 29,4 CEREBRAL HEMORRHAGE N.A. METFORMIN+INSULIN
MEAN 65,36 8M/6F 85,64 1,76 27,56 9,00
± SEM 7,92 11,82 0,09 2,83 5,43
The details of the diabetic organ donors. Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0028050.t002
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Figure 1. Reduced b-cell mass, enhanced PCNA+ b- and a-cells and altered expression of insulin signaling and cell adhesion proteins
in pancreas from patients with T2DM. Representative confocal mages of pancreas sections from type 2 diabetic and control pancreas showing
(a) quantification of islet cell number with immunostaining for insulin (red), glucagon (blue) and somatostatin (red); PCNA+ cells co-staining with (b)
insulin or glucagons (red) and PCNA (green) and (c) CK19 (green), PCNA (red) and insulin (blue); (d) alterations in expression of b-catenin with
immunstaining for PCNA (blue), b-catenin (green), insulin (red), light blue in the merged image indicates co-localization between b-catenin and PCNA;
(e) alterations in E-cadherin with immunostaining for PCNA (blue), E-cadherin (green) and insulin (red) and the merged image in yellow;
Immunostaining of pancreas sections for (f) insulin receptor a-subunit (green), insulin (red) and glucagon (blue); (g) BAD (green) and insulin (red) and
merged image in yellow; (h) phospho-BAD (green), insulin (red) and merged image in yellow, and (i) the cell-cycle inhibitor p27-kip1 (green), insulin
(red) and glucagon (blue), (n= 7). Yellow in merged images indicates co-localization between insulin staining and insulin signalling proteins.
Immunostaining was performed as described in Methods. Bars = 50 mm. *, p,0.05 controls vs T2D.
doi:10.1371/journal.pone.0028050.g001
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promoter or RIP-Cre) were generated as reported earlier [39]. Cell
lines from Control and bIRKO mice were derived as described
previously [40] . For islet studies, islets were isolated by the
intraductal technique [40]. Islets and cultured b-cells from control
and bIRKO mice were synchronized with hydroxyurea. Briefly,
freshly isolated islets were cultured for 48 hours in RPMI-1640
medium containing 7 mM glucose and 10% FBS. The islets were
then exposed to culture media containing 10 mM hydroxyurea for
16 hours. The hydroxyurea was removed by carefully rinsing islets
in RPMI 1640 media before continuing culture. For DNA
content, cells were collected by trypsinization, washed with PBS,
fixed with 70% ethanol and kept at 220uC until analysis. The
fixed cells were washed with PBS, stained with propidium iodide
solution and analyzed using flow cytometry. Cell-cycle profiles
were determined by Cell Quest and ModFit softwares. Insulin
receptors were re-expressed in bIRKO cells as reported earlier
[41].
Cytosolic and nuclear fractions and immunoblotting
Cytosolic and nuclear fractions were prepared by lysing cells
[42]. The fractionated lysates were subjected to immunoblotting
and visualized by an enhanced chemiluminescence system
(Roche). Antibodies recognizing Akt, FoxO1, p-FoxO1, cell-cycle
proteins and PTEN were purchased from Cell Signaling (Beverly)
and p27-Kip1 from BD Biosciences (San Diego). Antibodies to
Cyclin D2, Cyclin D3 and Cyclin E were obtained from Santa
Cruz, and to IRS-1, IRS-2 and phosphotyrosine (4G10) were from
Upstate (Waltham).
Statistical Analyses
All data are expressed as means + SEM. Differences between
control and diabetic groups were determined using Student’s
independent ‘t’ test or ANOVA as appropriate and ‘P’,0.05 was
considered significant.
Results
To evaluate the relative proportion of islet cells we immunos-
tained pancreas sections with antibodies against insulin, glucagon
and somatostatin. We did not observe differences in islet numbers
between groups. Consistent with earlier reports, we observed a
56% decrease in b-cells mass (p = 0.03) and an ,8% increase in a-
cell mass that did not reach statistical significance (p = 0.41) while
somatostatin cell mass was similar (p = 0.68) in pancreas sections
from patients with T2DM compared to controls (Fig. 1a)
[14,15,16].
A large number of PCNA+ (proliferating nuclear cell antigen)
cells that co-stained with insulin or glucagon in sections from
diabetic patients indicated that both b- and a-cells are engaged in
cell-cycle progression (Fig. 1b). In addition, in T2DM pancreases
PCNA+ cells that co-stained for cytokeratin 19, a marker of
exocrine cells, indicated proliferation in duct cells (Fig. 1c). The
lack of significant alterations in PCNA+ cells that co-stained with
somatostatin suggested the effects are specific to a- and b-cells
(data not shown). In addition, we did not detect Ki67-
immunoreactivity in islets cells in diabetic pancreases (data not
shown).
b-cell regeneration in rodents has been reported to involve a
process of de-differentiation and redifferentiation or epithelial-to-
mesenchymal-like transition (EMT) [28,30]. Whether this occurs
in vivo in humans is unknown. We therefore immunostained
pancreas sections with antibodies against E-cadherin and b-
catenin – two important markers of the cadherin-catenin adhesion
family of proteins known to be involved in EMT [43]. E-cadherin
was clearly detectable in membranes of b-cells in the controls but
reduced in the diabetic group (Fig. 1d). By contrast, b-catenin was
co-localized with PCNA in the nucleus only in the diabetic group
(Fig. 1e).
Insulin and IGF-I signaling pathways play important roles in
modulating the function/proliferation of islet b-cells and disrup-
tion of insulin receptors in mouse b-cells leads to a phenotype that
mimics human T2DM [39,44]. A reduced expression in insulin
receptor levels was evident in islets and acinar tissues of patients
with T2DM (Fig. 1f). Next, we examined expression of down-
stream signaling proteins BAD and phospho-BAD that are known
to be important in the apoptotic pathway [45]. While BAD protein
was expressed in both groups, p-BAD protein was virtually absent
in b-cells in the diabetic group suggesting enhanced apoptosis in
the pancreases from the type 2 diabetes cases who also exhibited
blunted insulin signaling (Fig. 1g,h). Considering the significant
increase in PCNA+ b-cells in patients with diabetes, we then
examined alterations in expression of proteins that regulate cell-
cycle. Consistent with our findings of reduced transcript levels for
the cell-cycle inhibitor, p27-kip1, we detected a marked decrease
in immunostaining for the protein in diabetic b-cells (Fig. 1i). To
examine the alterations in insulin receptor expression, we
extracted RNA from islets isolated from patients with T2DM
and controls, and subjected them to RT-PCR. Insulin receptors
exist as two isoforms in mammalian tissues – A and B [9,46].
Consistent with our earlier reports, we observed the expression of
both A and B isoforms were significantly reduced in diabetes
patients compared to controls (Fig. 2a) [19]. However, when the
data were expressed as a ratio of the two isoforms we did not
observe significant differences between groups (normal 0.6360.1
vs diabetes 0.5660.03, p=NS). Examination of cell-cycle proteins
showed a decrease in expression of the cyclin dependent kinase
cdk2, p27-kip1 and a trend towards a decrease in expression of
p21 (p= 0.08) in the diabetic group (Fig. 2b,c). We examined the
alterations in the expression of proteins in the insulin signaling
pathway in islets isolated from controls and patients with T2D. We
did not observe significant alterations between groups in the
expression of insulin receptors suggesting a differential regulation
of the mRNA and protein (Fig. 2d). However, the expression of
both total and tyrosine-612 levels of IRS-1 and IRS-2 (Fig. 2 e–h)
and total PI3-kinase (Fig. 2i) were significantly lower in T2D cases.
These data demonstrate a significant alteration in expression of
insulin signaling proteins multiple cell-cycle proteins that poten-
tially contributed to an inadequate b-cell hyperplastic response to
overcome insulin resistance, and/or enhanced the susceptibility of
b-cells to apoptosis, in the patients with diabetes.
Insulin signaling in b-cell cycle regulation
To gain insight into the molecular pathways that link b-cell-
cycle with insulin signaling, we took advantage of a mouse model
lacking functional insulin receptors in b-cells (bIRKO). A notable
feature of the bIRKO mouse is a decrease in b-cell mass
suggesting that absence of insulin signaling directly influences b-
cell regeneration in the mutants [39,44]. Therefore we studied b-
cell lines and isolated islets derived from three control and three
knockout mice using previously described methods [40].
A striking feature of b-cells derived from bIRKO mice was the
extremely slow growth compared to control b-cell lines (Fig. 3a).
The absence of significant differences in size prompted us to
examine cell-cycle control in the bIRKO group (Fig. 3b). Indeed,
DNA content analysis using propidium iodide staining of bIRKO
cells revealed a higher Go/G1 phase and reduced G2 population,
suggesting an impaired ability to transit from G1 to S phase
(Fig. 3c). To evaluate this possibility we synchronized cultured b-
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cells by hydroxyurea treatment for 16 hours and released the cells
from quiescence by culturing cells in the presence of serum. Eight
hours after release, ,62% of control cells entered S phase
compared to only ,18% of bIRKOs, providing direct evidence
that the slow growth of mutant b-cells is due to G1 to S phase
arrest (Fig. 3d).
To analyze the expression of proteins in regulation of cell-cycle
progression we examined cyclins, cyclin-dependent kinases (CDK)
and CDK inhibitors [47]. Similar to findings in the diabetic group,
the levels of expression of CDK2 were virtually absent in cultured
bIRKO cells, and CDK4, an important regulator of cell-cycle was
also significantly down-regulated (,85%) in mutant b-cells
(Fig. 4a). We also observed a .80% reduced expression in cyclin
D2 and D3 and a 42% reduction in cyclin E expression (Fig. 4b)
[25]. Consistent with data in human pancreas, we observed a
slight but significant increase in PCNA+ b-cells in bIRKO islets
(0.1160.04 vs 0.1760.03% b-cells, n=3, p,0.05) suggesting an
attempt by the cells to proliferate. Together, these changes are
consistent with a block in cell-cycle progression in bIRKO b-cells.
To identify key proteins that link insulin signaling with b-cell
proliferation we explored the expression and nuclear localization
of FoxO1. Protein levels for FoxO1 were up-regulated by three to
five-fold and restricted to nuclear fractions in bIRKO cells
(Fig. 4c). The fraction of FoxO1 that was phosphorylated was also
Figure 2. Reduced transcript levels of insulin signaling and cell-cycle proteins and protein levels of insulin signaling components in
islets isolated from patients with T2DM. (a) Expression of insulin receptor isoforms A and B; (b) transcript levels of insulin signaling proteins, and
(c) transcript levels of cell-cycle proteins. Data are expressed after normalization for TATA binding protein (TBP) (n= 5–7); *, p,0.05; ***, p,0.001;
controls vs T2DM. (d) protein expression of total insulin receptors, (e), total insulin receptor substrate-1, (f) total insulin receptor substrate-2, (g),
tyrosine-612 IRS-1, (h) tyrosine-612 IRS-2, (i) or total phosphatidyl inositol 3-kinase. *,p,0.05; **,p,0.001 Control vs T2D. Data in 2d–i are
immunoprecipitates. (j) b-actin was used to normalize the data in Figures 2d–i.
doi:10.1371/journal.pone.0028050.g002
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significantly lower in b-cells of the bIRKO mice in cytosolic (1468
vs 81618%; n=3, p,0.05) and nuclear fractions (18611 vs
68616%; n=3, p,0.05). Thus, a lack of functional insulin
receptors in b-cells leads to significantly reduced phosphorylation
and nuclear restriction of FoxO1.
To directly rescue the defects observed in the bIRKO cells, we
established stable b-cell lines expressing the human insulin
receptor B isoform (bIRKO-hIRB cells) [40,48]. Expression of
CDK2, CDK4 and cyclin E proteins (Fig. 4d) and tyrosine
phosphorylation of IRS2 and p-S473-Akt were restored (Fig. 4e)
and expression of FoxO1 was significantly reduced in nucleus and
increased in cytosolic fractions (Fig. 4f). Consequently, prolifera-
tion of insulin receptor re-expressing b-cells showed a significant
increase in DNA synthesis compared to bIRKO cells (Fig. 4g).
Figure 3. Insulin receptor-deficient b-cells exhibit slow growth and block in G1 to S-phase transition. (a) Defects in growth of bIRKO cells
is evident from total number of cells 4 and 12 days after the same number of cells are plated at day 0; the panel on the right shows poor spread and
clumping of bIRKO cells (b) b-cell size in control and bIRKO cell lines and islets determined by FACS analyses with forward scatter; (c) significantly
lower G1 and G2 in bIRKO cells, and (d) block in G1 to S-phase transition in bIRKO cells after synchronization with hydroxyurea for 18h. Analyses were
performed by FACS. In each case, representative data from 3 clones each derived from 3 RIP-Cre controls and 3 bIRKO mice are shown.
doi:10.1371/journal.pone.0028050.g003
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Figure 4. Insulin receptor-deficient b-cells show reduced expression of cyclins and cyclin dependent kinases and nuclear restriction
of FoxO1. (a) Reduced expression of cdk2 and cdk4; (b) reduced expression of cyclin D2, cyclin D3 and cyclin E; (c) increased expression and nuclear
restriction of FoxO1; (d) re-expression of the insulin receptor in bIRKO b-cells (bIRKO+hIRB) restores the expression of CDK2, CDK4 and cyclin E. Actin
is used as a loading control; (e) reduced p-IRS2 and p-S473-Akt in bIRKO and restoration of total IRS2, pIRS2 and p-S473-Akt in insulin receptor re-
expressing cells (bIRKO+hIRB); (f) Re-expression of insulin receptors in bIRKO cells restores FoxO1 to nucleus; (g) proliferation analyzed by the
deuterated water technique [57]. Representative data from at least 3 independent Western blotting experiments from at least 2 independent clones
are shown. The plots below the blots are shown in arbitrary units. The loading control for experiments in Fig. 4a–c is presented under the blot for
cyclin D3 in Fig. 4b. *, p,0.05 bIRKO vs Control or bIRKO+hIRB.
doi:10.1371/journal.pone.0028050.g004
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Discussion
Consistent with earlier reports [14,15,16,17], we observed
reduced b-cells and increased a-cells in patients with type 2
diabetes. Interestingly, we detected a striking increase in the
number of a- and b-cells that co-stained with the proliferation
marker, PCNA, suggesting that both a- and b -cells are attempting
to enter the cell cycle. These data may have important
implications for therapeutic efforts to counter hyperglycemia in
patients with type 1 or type 2 diabetes that are focused on the
regenerative potential of b-cells.
Insulin/IGF-I signaling mediates diverse pathways to modulate
proliferation and anti-apoptosis in most mammalian cells includ-
ing pancreatic islets [3,13] . Recent studies in humans and in
rodent models of insulin resistance, diabetes and obesity implicate
an important role for insulin/IGF-I signaling in b-cell biology
[9,13,33,39,40,41,44,46]. The significant decrease in insulin
receptor expression in islets from patients with type 2 diabetes
indicates that blunted insulin signaling in b-cells may make them
susceptible to apoptosis [9,19]. Alterations in phosphorylation of
the pro-apoptotic protein BAD are known to modulate apoptosis.
Thus, a reduced phosphorylation of BAD in the diabetic pancreas
is consistent with an increased apoptosis in type 2 diabetes that
possibly occurs, in part, secondary to hyperglycemia [8,15]. In
contrast, the higher a-cell mass may reflect the resistance of a-cells
to apoptosis in patients with type 2 diabetes and is associated with
higher circulating levels of glucagon [6,7,9,17]. We have
previously reported that human islets that have been transplanted
in streptozotocin-treated diabetic SCID mice exhibit a-cells that
are resistant to hyperglycemia-induced apoptosis, in contrast to the
apoptosis-susceptible b-cells [49,50].
Studies in rodents indicate that b-cell replication is a major
mechanism that contributes to maintaining adult b-cell mass
[22,25,28] Our observations of a striking increase in the number of
PCNA+ cells clearly indicates that human islet cells are also
capable of entering the cell cycle. The significant increase in the
number of PCNA+ b-cells in the diabetic group indicates that
either the b-cells are attempting to replicate as a compensatory
response to peripheral insulin resistance and/or that the increase
in PCNA expression is a DNA repair response to overcome the
effects of pro-apoptotic stimuli including elevated circulating levels
of glucose and free fatty acids - a consistent pathological feature of
type 2 diabetes [51,52,53]. It is worth noting that replicating b-
cells are more susceptible to cell death induced by islet amyloid
polypeptide that accumulates in b-cells in patients with type 2
diabetes [52]. Furthermore, consistent with the findings regarding
an increase in PCNA expression in conditions of cell stress, in
Affymetrix gene expression studies, we have observed a 40-fold
increase in the expression of PCNA mRNA in human islets of
Langerhans that have been cultured for five days as compared to
24 hours (Folli F, Perego L, Davalli A, unpublished observations),
a condition in which significant b-cell apoptosis can be detected
[8,49,50]. The lack of significant differences in PCNA mRNA in
islet samples (Fig. 2a) may be due to presence of multiple cell types
in islets and/or differential regulation of PCNA at the transcrip-
tional versus post-translational levels in b-cells [54]. While these
possibilities are not mutually exclusive, the reduced b-cell mass
clearly indicates an abortive attempt of the PCNA+ cells to
progress through the cell cycle and develop into functional b-cells
with a normal life span. The down regulation of key cell cycle
proteins including p27-kip1 and cdk2 in the diabetic pancreas
provides additional evidence for altered islet cell cycle dynamics
Figure 5. Schematic linking the growth factor pathway to defects in cell cycle progression and apoptosis in diabetic b-cells.
doi:10.1371/journal.pone.0028050.g005
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that could promote a default pathway towards apoptosis in b-cells.
For example, p27-kip1, in addition to inhibiting cyclins also acts as
an anti-apoptotic factor and the low expression of the protein in b-
cells may accelerate the apoptotic process [55,56]. This is
compounded by a concomitant reduction in the expression of
CDK2, CDK4 and cyclin E proteins, which are essential for
multiple steps in the transition from G1 to S phase of the cell cycle.
In addition to anti-apoptosis, insulin signaling regulates the
transcription factor FoxO1 that, in turn, interacts with PDX-1 to
modulate b-cell proliferation [29]. The near complete reversal of
nuclear restriction of FoxO1 and rescue of blunted proliferation by
re-expression of the insulin receptor in bIRKO cells [57] indicates
a direct link between insulin signaling and b-cell-cycle control.
FoxO proteins, including FoxO1, have been implicated in cell
cycle regulation [58]. For example, stress-induced FoxO activation
has been reported to alter the expression of genes that contribute
to cell cycle arrest [59]. Additional studies are necessary to
investigate the proteins that are directly activated by FoxO1 to
modulate islet cell cycle progression. Free fatty acids are also
known to modulate expression of insulin signaling proteins in vitro
[53]. Although we did not observe alterations in expression of
enzymes involved in lipid metabolism in diabetic islets (data not
shown), it is possible that ectopic lipid deposition in islets could
produce some of the changes observed in the diabetic group and
requires further study.
In conclusion, we propose that b-cells in patients with T2DM
are able to enter the cell-cycle, but fail to proliferate successfully to
compensate for peripheral insulin resistance due to dysfunctional
insulin signaling and cell-cycle arrest (Fig. 5). Restoration of insulin
signaling and cell-cycle control in b-cells may be one approach to
plan therapeutic strategies to counter b-cell loss in T2DM.
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